CSIMarket
 
Edwards Lifesciences Corporation  (EW)
Other Ticker:  
 
 
Price: $87.0400 $-0.94 -1.068%
Day's High: $88.2 Week Perf: -3.65 %
Day's Low: $ 86.57 30 Day Perf: 0.71 %
Volume (M): 2,592 52 Wk High: $ 96.12
Volume (M$): $ 225,608 52 Wk Avg: $80.47
Open: $87.80 52 Wk Low: $60.57



 Market Capitalization (Millions $) 52,581
 Shares Outstanding (Millions) 604
 Employees 15,700
 Revenues (TTM) (Millions $) 6,142
 Net Income (TTM) (Millions $) 1,410
 Cash Flow (TTM) (Millions $) 353
 Capital Exp. (TTM) (Millions $) 290

Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the worlds leading manufacturer of tissue heart valves and repair products used to replace or repair a patients diseased or defective heart valve. The Company is also a global leader in hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting.

Cardiovascular disease is the number-one cause of death in the world, and is the top disease in terms of health care spending in nearly every country. Cardiovascular disease is progressive in that it tends to worsen over time and often affects an individuals entire circulatory system.

The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular.

Patients undergoing surgical treatment for cardiovascular disease may be treated using a variety of Edwards Lifesciences products and technologies. For example, an individual with a heart valve disorder may have a faulty valve. A clinician may elect to remove the valve and replace it with one of Edwards Lifesciences bioprosthetic surgical tissue heart valves, surgically re-shape and repair the faulty valve with an Edwards Lifesciences annuloplasty ring, or deploy an Edwards Lifesciences transcatheter valve via a minimally invasive catheter-based system. If a patient undergoes open-heart surgery, Edwards Lifesciences Cardiac Surgery Systems products may be used while the patients heart and lung functions are being bypassed, or used during minimally invasive valve surgery. Virtually all high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function monitored by Edwards Lifesciences Critical Care products. If the circulatory problems are in the limbs rather than in the heart, the patients procedure may involve some of Edwards Lifesciences Vascular products, which include various types of balloon-tipped catheters that are used to remove blood clots from diseased blood vessels.

Edwards Lifesciences principal executive offices are located at One Edwards Way, Irvine, California 92614. The telephone number at that address is (949) 250-2500.

Competition

The medical device industry is highly competitive. Edwards Lifesciences competes with many companies, ranging from small start-up enterprises to companies that are larger with broader product offerings than Edwards Lifesciences. Furthermore, new product development and technological change characterize the areas in which Edwards Lifesciences competes. The present or future products of Edwards Lifesciences could be rendered obsolete or uneconomical as a result of technological advances by one or more of Edwards Lifesciences present or future competitors or by other therapies, including drug therapies. Edwards Lifesciences must continue to develop and acquire new products and technologies to remain competitive in the cardiovascular medical device industry. Edwards Lifesciences believes that it competes primarily on the basis of clinical superiority and innovative features that enhance patient benefit, product reliability, performance, customer and sales support, and cost-effectiveness.

The cardiovascular segment of the medical device industry is dynamic and subject to significant change due to cost-of-care considerations, regulatory reform, industry and customer consolidation, and evolving patient needs. The ability to provide products and technologies that demonstrate value and improve clinical outcomes is becoming increasingly important for medical device manufacturers.

Edwards Lifesciences believes that it is globally one of the leading competitors in each of its major product lines. The Companys products and technologies face substantial competition from a number of companies including divisions of companies much larger than Edwards Lifesciences and smaller companies that compete in specific product lines or certain geographies. In Surgical and Transcatheter Heart Valve therapies, the Companys primary competitors include St. Jude Medical, Inc., Medtronic, Inc. and Sorin Group. In Critical Care, Edwards Lifesciences competes primarily with a variety of companies in specific product lines including ICU Medical, Inc., PULSION Medical Systems AG and LiDCO Group PLC.



   Company Address: One Edwards Way Irvine 92614 CA
   Company Phone Number: 250-2500   Stock Exchange / Ticker: NYSE EW
   


Customers Net Income grew by EW's Customers Net Profit Margin grew to

44.29 %

3.89 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BSX   -0.52%    
ABT   -3.9%    
• View Complete Report
   



Edwards Lifesciences Corporation

Edwards Lifesciences Corporation Shows Strong Quarter with 3.57% Increase in Earnings Per Share

Edwards Lifesciences Corporation, a leading medical device company, has reported strong financial results for the quarter ended March 31, 2024. The company's revenue reached $1.60 billion, showing a year-on-year growth of 9.455% and a quarter-on-quarter growth of 4.166%. However, the earnings grew only slightly by 3.57% to $0.58 per share, with a sequential decrease of -5.07%.
In comparison to its competitors in the Medical Equipment & Supplies industry, Edwards Lifesciences has fallen short of business growth, with a growth rate of 9.53% lower than its contemporaries. Despite this, the company's earnings for the first quarter of 2024 increased by 3.08% to $351.000 million compared to the same period a year ago.

Product Service News

Edwards Lifesciences Shows Strong Performance with Continued Excellent Outcomes for TAVR Patients

Published Mon, Mar 11 2024 6:00 PM UTC

Edwards Lifesciences, a leading medical device company, has announced the promising results from two large, real-world studies conducted using TVT Registry data. The studies highlight the continued success of patients treated with the Edwards SAPIEN valve platform. Notably, the latest SAPIEN 3 Ultra RESILIA valve demonstrated lower rates of complications and improved patient...

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation's Earnings Suffer Despite Strong Revenue Surge in Q4 2023

Edwards Lifesciences Corporation, a leading Medical Equipment & Supplies company, recently reported its financial results for the quarter ended December 31, 2023. While the company experienced a notable rise in revenue, it encountered a reduction in earnings per share (EPS).
During the most recent fiscal period, Edwards Lifesciences Corporation witnessed a decrease in EPS of -5.96%, amounting to $0.61 per share. However, its revenue increased substantially by 13.751% to $1.53 billion compared to the same reporting period in the previous year. This revenue growth outperformed its sector contemporaries, as the rest of the Medical Equipment & Supplies sector reported only a 3.69% rise in revenue during the same period.

Product Service News

Edwards EVOQUE Valve Replacement System: Revolutionizing Tricuspid Valve Treatment and Boosting Edwards Lifesciences' Revenue

Published Fri, Feb 2 2024 12:00 PM UTC

In a breakthrough announcement, Edwards Lifesciences Corporation has received U.S. Food and Drug Administration (FDA) approval for its EVOQUE tricuspid valve replacement system. This cutting-edge transcatheter therapy marks a significant milestone as the first of its kind for treating tricuspid regurgitation (TR), a condition characterized by the backflow of blood from the r...

Business Update

Edwards Lifesciences Empowers Future Growth with Strategic Focus and Technology Advancements.

Published Thu, Dec 7 2023 1:30 PM UTC

Edwards Lifesciences Outlines Growth Strategy and Technology Pipeline at Investor Conference
Edwards Lifesciences Corporation, a leading medical technology company, recently held its annual investor conference where it unveiled its sharpened focus and growth strategy for the future. The conference also provided an update on the company's technology pipeline and shared fi...






 

Edwards Lifesciences's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Edwards Lifesciences announced annual revenue outlook on

Earnings Outlook
Edwards Lifesciences Corporation issued annual earnings guidance on

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com